Background-Previously, we identified 3274 distinct differentially expressed genes in abdominal aortic aneurysm (AAA) tissue compared with nonaneurysmal controls. As transcriptional control is responsible for these expression changes, we sought to find common transcriptional elements in the promoter regions of the differentially expressed genes. Methods and Results-We analyzed the up-and downregulated gene sets with Whole Genome rVISTA to determine the transcription factor (TF) binding sites overrepresented in the 5-kb promoter regions of the 3274 genes. The downregulated gene set yielded 144 TF binding sites that were overrepresented in the subset when compared with the entire genome. In contrast, the upregulated gene set yielded only 13 distinct overrepresented TF binding sites. Interestingly, as classified by TRANSFAC, 8 of the 13 TFs binding to these regions belong to the ETS family. Additionally, nuclear factor kB and its subunits p50 and p65 showed enrichment. Immunohistochemical analyses of 10 TFs from the upregulated set showed 9 to be present in AAA tissue. Based on gene ontology analysis of biological process categories of the upregulated target genes of enriched TFs, 10 TFs had enrichment in immune system process among their target genes. Conclusions-Our genome-wide analysis provides further evidence of ETS and nuclear factor kB involvement in AAA.
Clinical Perspective on p 572
Recently, we generated genome-wide expression profiles comparing gene expression in AAA tissue with age-, sex-, and ethnicity-matched nonaneurysmal control aorta using 2 different microarray platforms yielding 3274 distinct genes whose expression was significantly altered in AAA. 5 These types of analyses offer critical insight into changes occurring at the mRNA level of a disease state. It is transcriptional control, however, that is fundamentally responsible for these expression changes. Therefore, integration of the expression data with genome sequence data to uncover transcriptional regulatory elements serves to provide more comprehensive information about complex diseases like AAA. An implicit hypothesis for this integrated approach is that sets of coregulated genes share regulatory motifs that are similar and that regulatory motifs overrepresented in these sets are responsible for driving gene expression changes. 6 Phylogenetic footprinting can be used to discover regulatory regions in human genomic DNA. [7] [8] [9] [10] This method relies on the concept that regions of noncoding DNA that are highly conserved across species have important biological functions and often contain binding sites for transcription factors (TFs). 11 Comparative genomics, along with a computational approach to integrate gene expression data with sequence data, has been used in a method coined "transcriptional genomics" and has uncovered novel transcriptional elements involved in human heart failure. 10 A similar approach in the study of AAA holds great importance, as the pathobiology of the disease is still poorly understood. 12 This study focused on the regulatory elements contained in the 5-kb promoter regions of the 3274 differentially expressed genes.
Methods

Gene Expression Studies
Our laboratory used 2 microarray platforms to generate global mRNA expression profiles for both aneurysmal (nϭ7) and nonaneurysmal (nϭ7) abdominal aorta. The details on these studies have been described previously, 5 and the microarray data can be obtained at the Gene Expression Omnibus database (Series no. GSE7084; http://www.ncbi.nlm.nih.gov/geo/).
In Silico Analysis to Identify Transcription Factor Binding Sites Enriched in Differentially Expressed Gene Sets
We analyzed the up-and downregulated gene sets separately to elucidate the TF binding sites (TFBSs) in the regulatory regions of the differentially expressed genes using a computational approach implemented in Whole Genome rVISTA 13 (http://genome.lbl.gov/ vista/index.shtml), a publicly available bioinformatics program. For a given set of genes, Whole Genome rVISTA generates a list of TFBSs that are overrepresented in the set when compared with the entire genome. The rVISTA tool identifies TFBSs based on the TRANSFAC Professional library 14 in interspecies sequence alignments and then determines which of the TFBSs are conserved to maximize the identification of functional sites. 15 Uncharacterized and poorly annotated genes were removed from the 3274 differentially expressed genes identified in our previous AAA microarray analysis. 5 This resulted in the removal of 150 (10%) genes from the upregulated gene set and 190 (11%) genes from the downregulated gene set. Upregulated (1331 genes) and downregulated (1603 genes) gene sets were then analyzed separately in Whole Genome rVISTA to search for human sequences (UCSC version hg18, NCBI Build 36.1) conserved in alignment with mouse (UCSC version mm8, NCBI Build 36). The 5-kb region upstream from the transcription start site of each gene was examined. Binomial distribution was used for statistical analyses with a probability value cutoff of 0.006. It should be noted that 20 (1.5%) of the 1331 upregulated and 23 (1.4%) of the 1603 downregulated genes were not found in the database, resulting in an analysis of 1311 and 1580 genes, respectively. An outline of the analyses is presented in Figure 1 . ; ‡Negative log base 10 of the probability value from the binomial distribution; §No transcription factor identified in human; Factors also bind as a heterodimer to the respective site. Whole Genome rVISTA reported monomeric binding sites for NFKB p65 and NFKB p50 in addition to the NFKB site.
The TRANSFAC database version 2008.3 (BIOBASE GmbH) was used to classify the TFs, known to bind to the TFBSs, in our analysis into families. 14 
Immunohistochemical Analysis
Control aorta samples (nϭ5; donor ages ranging from 58 to 87 years) were obtained at autopsy. Patient samples (6 AAA patients; ages ranging from 63 to 87 years) were tissues removed from the aneurysmal sac during surgical repair operations to trim the area for fitting the prosthesis (supplemental Table I ). Samples from other tissues were obtained during autopsies. The study was approved by The Institutional Review Board of Wayne State University.
Immunostaining was carried out with formalin-fixed paraffinembedded tissue sections as described previously. 16 The slides were incubated with a primary antibody against the protein of interest (Santa Cruz Biotechnology: anti-PEA3, sc-113; anti-ELF1, sc-631; anti-ETS2, sc-22803; anti-ETS1, sc-350; anti-nuclear factor kB [NFKB] p65, sc-8008; anti-NFKB p50, sc-114; anti-GABP-␣, sc-28311; anti-TEL2, sc-102131; anti-NERF, sc-6829; and anti-ISRE [anti-STAT1], sc-592. Genetex: anti-RUNX1, GRX94183). A secondary antibody with avidin-biotin peroxidase amplification (Dako: LSAB2) was used, and the signal was detected using diaminobenzidine as a chromogen. Antibodies for each protein were first tested on tissue known to contain the protein of interest as positive controls. Nonspecific IgG antibody in lieu of primary antibody served as a negative control.
Biological Process Analysis of Target Genes
The down-and upregulated gene sets were used to identify enriched Gene Ontology (GO) biological process (BP) categories with a software package available using R and Bioconductor. 17, 18 Then, Whole Genome rVISTA was used to subcategorize genes in the upregulated gene set according to the overrepresented TFBSs they contain for ELF1, ETS2, ETS1, NFKB, NFKB P65, NFKB P50, GABP, TEL2, ISRE, AML1, and NERF. PEA3 and c-ETS 1 to 68 were excluded from the analysis, because no expression in aortic tissues was detected for PEA3, and no human TF binding to the TFBS c-ETS 1 to 68 was found. These gene lists were then used to identify enriched GO BP categories they have in common using WebGestalt (Web-based Gene Set Analysis Toolkit; http://bioinfo.vanderbilt.edu/webgestalt). 19, 20 GO analysis was performed using the hypergeometric test to determine overrepresentation of terms in the gene set compared with the 18 057 distinct genes represented on both Affymetrix and Illumina arrays based on our initial microarray studies. 5 Directed acyclic graphs were generated to provide visual presentation of the hierarchical nature of the GO categories. They were redrawn in Adobe Illustrator (version 12.0.1; Adobe Systems Inc) to provide high-resolution images.
Results
The 1580 genes identified as downregulated in AAA in our previous microarray analyses 5 contained 144 overrepresented TFBSs in their 5-kb promoter regions when compared with the entire genome (supplemental Table II Tables II and III) . A GO analysis, looking for enrichment in BP categories, showed that the group of 1242 (77.5% of the total number of genes) downregulated genes with GO annotations was enriched among others for GO terms cell adhesion, muscle development, cell morphogenesis, and cell-matrix adhesion (supplemental Table IV) .
Analysis of the promoter regions of the 1311 genes upregulated in AAA yielded only 13 overrepresented TFBSs when compared with the entire genome (Figures 1 and 2) . Of these 1311 genes, 981 (75%) genes contained binding sites for at least 1 of the 13 overrepresented TFs, with a range of 1 (154 genes) to 12 factors (MMP9; Figure 3 ) and an average of 4.2 TFs per gene (supplemental Table V) .
When classified by TRANSFAC, 8 of the 13 enriched TFBSs in the upregulated gene set had binding proteins belonging to the ETS-type family of TFs (Figure 2 ). Additionally, NFKB and its heterodimeric subunits p65 and p50 showed enrichment in our analysis (Figure 2 ).
Immunohistochemical analysis was carried out for 10 of the 13 TFs enriched in the upregulated gene set to determine whether the proteins were present both in nonaneurysmal aorta and AAA tissue. TF c-ETS 1-68 was not analyzed because no human protein binding to the TFBS has been identified, NERF was not analyzed, because the antibody used failed to show staining even in the positive control samples, and TEL2 was not analyzed because of high background in the antibody staining. Staining in aneurysmal tissue was positive for ELF1, ETS1, ETS2, NFKB p65, NFKB p50, GABP␣, ISRE (STAT1), and AML1 in at least some component of the aortic media or adventitia ( Figure 4) and negative for PEA3. The immunohistochemical results were in reasonable agreement with mRNA expression data from our microarray studies 5 in that all of the proteins tested in our immunohistochemical analysis aside from PEA3 were detected (Figures 4 and 5; supplemental Table VI) . PEA3 was not detectable on the mRNA level either (supplemental Table VI ). TEL2 had a robust mRNA signal (supplemental Table VI ), but because of technical problems we did not succeed in the immunohistochemical analyses for TEL2. It is of interest that 3 of the TFs, ELF1, AML1 (RUNX1), and ISGF-3 (the gene 
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symbol for ISGF-3 which binds to ISRE is STAT1), had significantly increased mRNA levels in AAA (supplemental Table VI; Figure 5 ). Next, a GO analysis was performed for the entire set of upregulated target genes. GO annotations were available for 91.8% of the genes. Many different GO categories related to immune function were among the most enriched GO categories (supplemental Table VII ). This analysis was followed up by analyzing the GO categories for the different subcategories of genes separately to determine whether genes in each set defined by presence of a specific TF were enriched for, or participated in, the same BPs. The analysis presented a total of 65 enriched BP categories among the genes containing binding sites for the 11 TFs listed in Figure 2 (PEA3 and c-ETS 1-68 were excluded from this analysis; supplemental Tables VIII and IX). As of December 2008, 840 of the 955 (88%) target genes submitted for analysis had GO annotations. Among the most significant BP categories were immune system process and immune response, in that genes with 10 of the 11 TFBS showed enrichment for immune system process and 9 for immune response. Furthermore, one or both of these were either the first or second most significant category for 9 of the 11 gene lists (supplemental Table IX ). Only the gene lists for ETS2 and NERF did not have these GO categories among the top most significantly enriched categories. The most enriched categories for ETS2 were signal transduction and cell communication, although immune system development, hemopoiesis, and hemopoietic or lymphoid organ development, which are immune-related, were also enriched categories. Genes containing NERF binding sites were also highly enriched for immune processes such as hemopoiesis, hemopoietic or lymphoid organ development, immune system development, and immune system process. The directed acyclic graphs for target genes of ELF1, AML1 (RUNX1), and ISGF-3 (STAT1) are shown in Figure 6 . 
Discussion
Although the underlying pathobiology of AAA remains largely unknown, the aneurysmal aortic wall is characterized by inflammation, vascular smooth muscle cell (VSMC) apoptosis, and degradation of the extracellular matrix (reviewed in 12, 22 ). Particular attention has focused on MMP9, which is an abundant proteinase secreted by human AAA organ cultures in vitro and is elevated in the plasma of AAA patients. 23, 24 Additionally, targeted gene disruption of Mmp9 in mice prevented AAA formation in the elastase-perfusion model. 24 Furthermore, inflammatory macrophage migration to the site of aneurysm requires activation of MMP9 by plasminogen in mice. 25 Considering its proven involvement in AAA pathogenesis, it is interesting that MMP9 contains at least 1 binding site in its 5-kb promoter region for 12 of the 13 enriched TFBSs in the upregulated gene set (Figure 3 ). ETS1 and NFKB, both of which have binding sites in the MMP9 promoter, have been previously investigated for their effect on MMP9 expression. In an organ culture of human aorta, transfection with ETS1 decoy oligodeoxynucleotides decreased MMP1 and MMP9 expression, 26 and in human VSMCs, overexpression of NFKB inhibitor, IB␣, decreased expression of MMP9, MMP1, and MMP3. 27 In addition to their effect on MMP gene expression, both NFKB and ETS1 also play a role in several other processes pertinent to AAA pathogenesis. AAAs exhibit VSMC apoptosis along with inflammation throughout the media and adventitia of the aortic wall (reviewed in 12 ). Immune infiltrates 28 -32 are present in AAA tissue and have been implicated in these processes. It is thought that loss of VSMC is a result of apoptosis and that macrophages and T cells participate in this process through their production of cytotoxic mediators such as cytokines, perforin, and Fas/FasL. 30 FasL is a downstream target of ETS1 in VSMCs derived from atherosclerotic lesions and targeted gene disruption of ETS1 decreased production of natural killer cells and interleukin (IL) 2, as well as diminished Th1-mediated T-cell responses (reviewed in 33 ) . NFKB is involved in T-cell activation and the induction of several inflammatory cytokines (reviewed in 34 ). In addition, ETS1 increased IL5 promoter activity in Jurkat T-cells. 35 The release of proinflammatory cytokines such as IL5 and IL6 by T-cells is thought to promote vascular inflammation at the site of AAA. 29 The above characteristics have made ETS1 and NFKB potential therapeutic targets in the AAA field. Inhibition of ETS1 by decoy oligodeoxynucleotides in a rat AAA model prevented aneurysmal dilatation and the destruction of elastin fibers in the aorta. 26 Simultaneous inhibition of ETS1 and NFKB using chimeric decoy oligodeoxynucleotides prevented AAA formation in both rat and rabbit models of AAA 36, 37 and demonstrated AAA regression in a rabbit model in which AAA was already established using elastase perfusion. 38 Additionally, upregulation of NFKB and ETS coincided with accelerated AAA formation in a rat hypertensive AAA model. 39 Surprisingly, we did not observe significant differences in the mRNA levels for the ETS1, ETS2, NFKBp50, or NFKBp65 between human AAA and control tissues.
Perhaps the most interesting discovery of this study was the finding that in the upregulated AAA gene set, all of the genes containing binding sites for ETS2 also contain ETS1 binding sites in their promoters (supplemental Table V ). Based on the sequence similarity (AGGA; Figure 2 ) in their TFBS matrices (TRANSFAC) and the fact that ETS2 sites are more restrictive based on the positional weight matrices model, ETS2 sites are actually a subset of ETS1 sites. One implication of the similarity in their recognition sequences, which has been mentioned previously, 33 is that targeting ETS1 binding sites using the decoy oligodeoxynucleotide methods 26,36 -38 mentioned earlier is unspecific and may lead to inhibition of ETS2 as well. It is, therefore, difficult to conclude whether the effects on MMP9 gene expression and AAA prevention resulted from ETS1 or ETS2 inhibition or some type of cooperative effect. This is further complicated by the fact that they both have conserved binding sites in the promoter region of MMP9 (Figure 3) . A study examining the effect of ETS TFs on the MMP9 gene promoter found that both ETS1 and ETS2 were able to activate MMP9 in response to endothelial growth factor. 40 The current genome-wide analysis reinforces the immune component of AAA as 10 of the 11 target gene lists among the upregulated genes showed enrichment in the BP category immune system process. Although immune-related categories were prominent for all of the target gene lists, a wide range of BPs were identified among the target genes, including signal transduction, physiological response to stimulus, and cell communication. The downregulated genes, however, showed enrichment in very different functional categories such as cell adhesion and cell morphogenesis, and no immune-related functions were identified among these genes.
Additionally, the study identified novel TFBSs enriched in the set of upregulated genes in AAA. AML1 (gene symbol: RUNX1; Runt-related TF 1) had a particularly interesting protein expression pattern based on immunohistochemistry. AML1 stained positive in both the vasa vasorum and the endothelial layer of the aortic wall (Figure 4) . The vasa vasorum have been implicated in AAA pathogenesis as both MMP2 and MMP9 as well as tissue inhibitors of MMPs colocalize in the vasa vasorum in AAA tissue. 41 Of additional importance is that many genes biologically relevant to AAA that were upregulated in our microarray studies contain binding sites for AML1 such as MMP9, several ILs and chemokines, as well as PLAU (supplemental Table V) . 42 Furthermore, the mRNA levels of RUNX1 were significantly increased in AAA compared with abdominal aortas obtained from age-, sex-, and ethnicity-matched controls (supplemental Table VI; Figure 5 ).
Limitations
One of the limitations of this study is that only the 5-kb promoter regions of the differentially expressed genes were examined for binding sites. Control elements can, and often do, exist outside of these regions. 43 In addition, only the conserved regions of these promoters were considered in the analysis. There is potential for regulatory binding sites in the human genome that are not shared with other species. 43 Also, only conservation with mouse was considered in the analysis, and it may be of benefit to extend the analysis with species phylogenetically closer and more distant to human. The lack of specificity in TFBSs is another limitation in the sense that it will artificially inflate the number of TFs assigned to each promoter of the target genes and thus creates the appearance that a family of TFs binds to a gene set. Most of these limitations can be addressed in future studies with experimental validation of the findings.
Conclusion
Our unbiased genome-wide analysis provides additional information on the role of the ETS family of TFs in the pathogenesis of AAA. Additionally, it identified other potential molecules for study. Future studies including chromatin immunoprecipitation and functional assays are needed to gain a better understanding of the roles the identified TFs play in AAA and the regulation of these gene sets. Taken together, these results might lead to the discovery of new therapeutic targets for the management of this deadly disease.
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